Journal of cardiothoracic and vascular anesthesia · 2025
Prophylactic Intravenous Tranexamic Acid in Thoracic Surgery: A Matched-pair Analysis From the German Thoracic Registry.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schieren Mark, Collaud Stephane, Bonberg Luis, Welters Jesko, Wappler Frank, Defosse Jérôme, working group of the German Thoracic Registry
Аннотация
OBJECTIVES: To evaluate the effect of prophylactic intravenous tranexamic acid (TXA) on bleeding complications, thromboembolic events, and hospital stay in patients undergoing thoracic surgery.
DESIGN: Retrospective matched-pair analysis of registry data.
SETTING: German Thorax Registry data from multiple thoracic surgery centers across Germany.
PARTICIPANTS: A total of 1,034 adult patients undergoing thoracic surgical procedures, matched 1:1 (517 received intravenous TXA, 517 did not).
INTERVENTIONS: Administration of prophylactic intravenous TXA prior to thoracic surgery.
MEASUREMENTS AND MAIN RESULTS: Postoperative bleeding complications, including reoperations for bleeding and transfusion requirements, did not differ significantly between groups. However, thromboembolic complications were significantly less frequent in the TXA group (1.0% v 5.1%). Cardiac complications were also less frequent in the TXA group. No significant differences were observed in overall complication rates or length of hospital stay.
CONCLUSIONS: Prophylactic intravenous TXA did not reduce bleeding complications in thoracic surgery but was associated with a lower incidence of thromboembolic and cardiac events. While no definitive conclusions can be made about the efficacy of TXA in reducing bleeding complications, the study offers insights into its potential role in reducing thromboembolic and cardiac complications. A well-powered, randomized controlled trial is needed to confirm these results.
DESIGN: Retrospective matched-pair analysis of registry data.
SETTING: German Thorax Registry data from multiple thoracic surgery centers across Germany.
PARTICIPANTS: A total of 1,034 adult patients undergoing thoracic surgical procedures, matched 1:1 (517 received intravenous TXA, 517 did not).
INTERVENTIONS: Administration of prophylactic intravenous TXA prior to thoracic surgery.
MEASUREMENTS AND MAIN RESULTS: Postoperative bleeding complications, including reoperations for bleeding and transfusion requirements, did not differ significantly between groups. However, thromboembolic complications were significantly less frequent in the TXA group (1.0% v 5.1%). Cardiac complications were also less frequent in the TXA group. No significant differences were observed in overall complication rates or length of hospital stay.
CONCLUSIONS: Prophylactic intravenous TXA did not reduce bleeding complications in thoracic surgery but was associated with a lower incidence of thromboembolic and cardiac events. While no definitive conclusions can be made about the efficacy of TXA in reducing bleeding complications, the study offers insights into its potential role in reducing thromboembolic and cardiac complications. A well-powered, randomized controlled trial is needed to confirm these results.